New Zealand vs United States: Proportion of isolates with decreased susceptibility or resistance
New Zealand
0.1
in 2020
United States
0
in 2020
New Zealand rank
11th
United States rank
13th
Proportion of isolates with decreased susceptibility or resistance over time
- New Zealand
- United States
How they compare
New Zealand currently reports 0.1 against 0 in United States, a difference of 0.1.
The two have swapped places 1 time across 10 shared years of data; in 2009 it was United States ahead.
New Zealand ranks 11th and United States ranks 13th of 52 countries.
Across the 3 decades both report, New Zealand averaged higher in 2 and United States in 1.
Head to head by decade
| Decade | New Zealand | United States | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0 | 0.2842 | 0.2842 | United States |
| 2010s | 0.3595 | 0.2393 | 0.1202 | New Zealand |
| 2020s | 0.1 | 0 | 0.1 | New Zealand |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher proportion of isolates with decreased susceptibility or resistance, New Zealand or United States?
- New Zealand, at 0.1 against 0 in United States as of 2020.
- What is the difference in proportion of isolates with decreased susceptibility or resistance between New Zealand and United States?
- 0.1, with New Zealand ahead.
- How many years of comparable data are there for New Zealand and United States?
- 10 years are reported by both, from 2009 to 2020.
- How do New Zealand and United States rank globally for proportion of isolates with decreased susceptibility or resistance?
- New Zealand ranks 11th and United States ranks 13th of 52 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP. Statizoid refreshes it automatically from the source and publishes the full history for both places.